Association between provincial income levels and drug prices in China over the period 2010–2017

Abstract

In the past decade, the Chinese central government has made sweeping reforms to national pharmaceutical policies. However, provincial authorities have retained control over most drug procurement procedures, potentially leading to cross-province differences in drug prices. The objectives of this study were to (i) examine drug price trends in 31 Chinese provinces and municipalities between 2010 and 2017; (ii) evaluate the association between provincial income levels and drug prices over this period; and (iii) compare the results for Chinese state-owned, Chinese private, and multinational pharmaceutical firms. Using publicly available data on procurement prices of the drugs manufactured by the top 30 pharmaceutical firms in China (in terms of revenues), we ran a generalized country-productdummy regression to compare drug prices across provinces over the study period. We conducted subgroup analyses to test for differences between types of firms. Between 2010 2 and 2017, drug prices decreased by an average of 23% across the country. The prices of drugs sold by multinational firms dropped by 32% over this period, while the prices of drugs sold by Chinese private firms declined by 28%. By contrast, the drug prices of state-owned firms went up by 11%. There were statistically significant positive associations between drug prices and provincial income levels for the full sample in 2010, 2011, and 2013. There were no significant associations in other years. Several low-income provinces paid higher procurement prices than some high-income provinces for identical medicines, especially in later study years. The lack of association between income levels and prices poses equity concerns and may place a heavier cost burden on the poor. It also suggests that China's pharmaceutical policies may be failing to balance the dual aims of drug affordability and incentives for innovation. HIGHLIGHTS• Drug procurement prices dropped by an average of 23% between 2010 and 2017 in China.• Trends in prices varied between drugs sold by different types of firms.• There was no association between prices and provincial incomes in most years.• This may have placed a heavier cost burden on poorer provinces.

Perceptions of the benefits of the basic medical insurance system among the insured: a mixed methods research of a northern city in China

“…For example, in 2018, China's total drug expenditure was 1,914.89 billion yuan, accounting for 32.39% of the total health expenditure, which is far higher than the average of 17% in OECD countries ( 51 ). In addition, the results of a survey on drug prices in 31 Chinese provinces showed that drug prices in Heilongjiang province, the area we investigated, were generally higher than the national average ( 52 ). He et al and Zeng et al believe that this is related to the high price and quantity of drugs used ( 53 , 54 ).…”

The impact of Chinese volume-based procurement on pharmaceutical market concentration

“…Thus, we take INN as the molecular boundary. Second, drug bidding and procurement is mainly carried out by provincial units in the Chinese mainland, and there are significant differences in the drug market among provinces ( Shi et al, 2020 ). Therefore, we set province/city as the geographical boundary.…”

The influence of the national drug price negotiation policy reform on the medical expenses of patients in Xuzhou City: an interrupted time series analysis

“…In the context of this policy, insured persons have access to reimbursement for negotiated medicines, which improves cost-effectiveness, and thereby reduces the burden ( 9 , 10 ). Since the implementation of the National Drug Policy, drug prices have been reduced by an average of 60.1%, reducing the burden on patients by >$90 billion ( 11 ).…”